How to Optimize Process Development for ADC Production

Antibody drug conjugates (ADCs) are highly targeted cancer therapies that link a monoclonal antibody to a cytotoxic drug via a chemical linker. Process development (PD) is foundational for ADC manufacturing as it ensures safety, efficacy, stability, and scalability of the final product. However, PD is also a multi-faceted, highly technical process requiring expertise in complex analytical methods.

Join this webinar to hear Alper Uras, Head of North America Fast Trak™ Process Development at Cytiva, talk best practices and how to avoid common pitfalls in ADC process development.

Key learning objectives

• Understand PD workflows needed in ADC development
• Learn how to avoid common pitfalls in PD
• Discover best practices from someone who works in PD everyday

Who should attend?

PD scientists, scale up, and upstream (USP) and downstream (DSP) professionals in the ADC space.

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.